{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T07:36:33Z","timestamp":1790753793273,"version":"4.1.0"},"reference-count":34,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T00:00:00Z","timestamp":1589414400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Translational Sci"],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:p>Toll\u2010like receptor 7 (TLR7) agonists modulate broad spectrum immune activity and are evaluated in the treatment of human diseases, including cancer and chronic viral infection. RO7020531, an oral prodrug of a TLR7 agonist, is in clinical development as part of a curative regimen against chronic hepatitis B. We report the safety, tolerability, pharmacokinetics (PKs), and pharmacodynamics (PDs) of RO7020531 in healthy Chinese volunteers following single and multiple ascending doses (SAD and MAD). PK and PD samples were evaluated from four SAD cohorts and 3 MAD cohorts with 10 subjects each (8 active and 2 placebo). Safety and tolerability were monitored throughout the study. A total of 155 adverse events (AEs) were reported in 49 subjects. Fifty\u2010one AEs in 18 subjects were assessed as treatment\u2010related. Most of the AEs were mild; nine subjects experienced moderate AEs; there were no severe AEs. In two 150\u00a0mg MAD cohorts given every other day (q.o.d.), 7 of 20 subjects experienced pyrexia and were discontinued due to transient asymptomatic lymphopenia, which resolved 24\u201348\u00a0hours postdose. The PK of the active metabolite, RO7011785, increased linearly with dose from 40\u00a0mg to 170\u00a0mg. There was no PK accumulation following q.o.d. dosing. The PK profile is consistent with observations in white subjects in the global first\u2010in\u2010human study. SADs and MADs of RO7020531 resulted in dose\u2010dependent increases in TLR7 response markers at 100\u00a0mg or above. Flu\u2010like symptoms were associated with higher interferon\u2010\u03b1 levels. RO7020531 was safe and acceptably tolerated in healthy Chinese volunteers with a multiple 150\u00a0mg q.o.d. dose regimen.<\/jats:p>","DOI":"10.1111\/cts.12791","type":"journal-article","created":{"date-parts":[[2020,4,8]],"date-time":"2020-04-08T17:57:10Z","timestamp":1586368630000},"page":"985-993","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["A Single and Multiple Ascending Dose Study of Toll\u2010Like Receptor 7 Agonist (RO7020531) in Chinese Healthy Volunteers"],"prefix":"10.1111","volume":"13","author":[{"given":"Andrea","family":"Luk","sequence":"first","affiliation":[{"name":"Phase 1 Clinical Trial Centre The Chinese University of Hong Kong Hong Kong SAR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiudi","family":"Jiang","sequence":"additional","affiliation":[{"name":"Roche Innovation Center Shanghai Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6789-8781","authenticated-orcid":false,"given":"Katerina","family":"Glavini","sequence":"additional","affiliation":[{"name":"Roche Innovation Center Basel Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Triyatni","sequence":"additional","affiliation":[{"name":"Roche Innovation Center Basel Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Zhao","sequence":"additional","affiliation":[{"name":"Roche Pharma Development Shanghai Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Racek","sequence":"additional","affiliation":[{"name":"Roche Innovation Center Basel Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghong","family":"Zhu","sequence":"additional","affiliation":[{"name":"Roche Innovation Center Shanghai Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph F.","family":"Grippo","sequence":"additional","affiliation":[{"name":"Roche Innovation Center New York New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,5,14]]},"reference":[{"key":"e_1_2_11_1_1","unstructured":"World Health Organization.Hepatitis B. Global Alert and Response (GAR)(2002) <https:\/\/www.who.int\/csr\/resources\/publications\/hepatitis\/WHO_CDS_CSR_LYO_2002_2\/en\/>."},{"key":"e_1_2_11_2_1","unstructured":"World Health Organization.Hepatitis B fact sheet. Updated July 2018 <https:\/\/www.who.int\/en\/news-room\/fact-sheets\/detail\/hepatitis-b>."},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02240"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.02.010"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-015-9675-4"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28156"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.021"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2055-6640(20)30302-2"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.02.016"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.05.008"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i24.7707"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60220-8"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.77.1.68-76.2003"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2542"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.15.9369-9380.2005"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni1112"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2013.11.024"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr588"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-12-129"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20119"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.11.7269-7272.2005"},{"key":"e_1_2_11_22_1","doi-asserted-by":"crossref","unstructured":"Gane E.et al.RO7020531 a novel prodrug of a toll\u2010like receptor 7 agonist is safe well tolerated and activates TLR signalling in healthy volunteers. EASL 2018; poster FRI\u2010337.","DOI":"10.1016\/S0168-8278(18)31277-7"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.3.1259"},{"key":"e_1_2_11_24_1","unstructured":"Yuen M.F.et al.Safety pharmacokinetic pharmacodynamic and viral data after 6\u2010weeks of dosing with TLR7 agonist RO7020531 in chronic hepatitis B patients. AASLD 2019; abstract 0692 (2018)."},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.05.008"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270007304780"},{"key":"e_1_2_11_27_1","unstructured":"Investigator's Brochure RO7020531 fourth version June 2019."},{"key":"e_1_2_11_28_1","unstructured":"Investigator's Brochure RO6864018 eighth version June 2016."},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12942"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.10.027"},{"key":"e_1_2_11_31_1","doi-asserted-by":"crossref","unstructured":"Dai L.et al.Combination treatment of a TLR7 agonist RO7020531 and a capsid assembly modulator RO7049389 achieved sustainable viral load suppression and HBsAg loss in an AAV\u2010HBV mouse model. EASL 2018; abstract PS\u2010028.","DOI":"10.1016\/S0168-8278(18)30253-8"},{"key":"e_1_2_11_32_1","doi-asserted-by":"crossref","unstructured":"Luk A.et al.A single and multiple ascending dose study of toll\u2010like receptor 7 (TLR 7) agonist (RO7020531) in Chinese healthy volunteers. APASL 2019; abstract 188.","DOI":"10.1111\/cts.12791"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-06-027599"},{"key":"e_1_2_11_34_1","unstructured":"Jiang Q. et al.Ascending dose pharmacokinetic (PK)\/pharmacodynamic (PD) bridging study of toll\u2010like receptor 7 (TLR 7) agonist (RO6864018) in Asian and Caucasian healthy subjects. APASL 2017; abstract OP\u2010117."}],"container-title":["Clinical and Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcts.12791","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.12791","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cts.12791","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.12791","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T18:23:29Z","timestamp":1693938209000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1111\/cts.12791"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,14]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["10.1111\/cts.12791"],"URL":"https:\/\/doi.org\/10.1111\/cts.12791","archive":["Portico"],"relation":{},"ISSN":["1752-8054","1752-8062"],"issn-type":[{"value":"1752-8054","type":"print"},{"value":"1752-8062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,14]]},"assertion":[{"value":"2020-01-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-08","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}